Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 6:9:827850.
doi: 10.3389/fmed.2022.827850. eCollection 2022.

Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on Severe Pneumocystis Pneumonia After Renal Transplantation

Zhun-Yong Gu  1 , Wen-Jun Liu  1 , Dan-Lei Huang  1 , Yu-Jing Liu  2 , Hong-Yu He  1 , Cheng Yang  3 , Yi-Mei Liu  1 , Ming Xu  3 , Rui-Ming Rong  3 , Du-Ming Zhu  1 , Zhe Luo  1 , Min-Jie Ju  1
Affiliations

Preliminary Study on the Combination Effect of Clindamycin and Low Dose Trimethoprim-Sulfamethoxazole on Severe Pneumocystis Pneumonia After Renal Transplantation

Zhun-Yong Gu et al. Front Med (Lausanne). .

Abstract

Objective: Evaluate the effect of the combination of clindamycin with low-dose trimethoprim-sulfamethoxazole (TMP/SMX) regimen on sever Pneumocystis pneumonia (PCP) after renal transplantation.

Method: 20 severe PCP patients after renal transplantation were included in this historical-control, retrospective study. A 10 patients were treated with the standard dose of TMP/SMX (T group), the other 10 patients were treated with the combination of clindamycin and low dose TMP/SMX (CT group).

Results: Although there was no significant difference in the hospital survival between the two groups, the CT protocol improved the PaO2/FiO2 ratio more significantly and rapidly after the 6th ICU day (1.51 vs. 0.38, P = 0.014). CT protocol also ameliorated the pulmonary infiltration and the lactate dehydrogenase level more effectively. Moreover, the CT protocol reduced the incidence of pneumomediastinum (0 vs. 50%, P = 0.008), the length of hospital staying (26.5 vs. 39.0 days, P = 0.011) and ICU staying (12.5 vs. 22.5 days, P = 0.008). Furthermore, more thrombocytopenia (9/10 vs. 3/10, P = 0.020) was emerged in the T group than in the CT group. The total adverse reaction rate was much lower in the CT group than in the T group (8/80 vs. 27/80, P < 0.001). Consequently, the dosage of TMP/SMX was reduced in 8 patients, while only 2 patients in the CT group received TMP/SMX decrement (P = 0.023).

Conclusion: The current study proposed that clindamycin combined with low-dose TMP/SMX was more effective and safer the than single use of TMP/SMX for severe PCP patients after renal transplantation (NCT04328688).

Keywords: Pneumocystis pneumonia; clindamycin; combination; renal transplantation; trimethoprim-sulfamethoxazole.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Patient-selection flow chart.
FIGURE 2
FIGURE 2
Daily P/F ratio of PCP patients after renal transplantation. For patients in the CT group, the P/F ratio had been elevated to more than 300 mmHg in the 6th ICU day. On the other hand, the P/F ratio of patients from T group could not be higher than 300 mmHg before the 12th ICU day.
FIGURE 3
FIGURE 3
Comparison of the improvement of P/F ratio between CT group and T group. After the 6th ICU day, the improvement of P/F ratio was more significantly in the CT group than in the T group.
See this image and copyright information in PMC

References

    1. Bollee G, Sarfati C, Thiery G, Bergeron A, de Miranda S, Menotti J, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. (2007) 132:1305–10. - PubMed
    1. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. (2002) 21:523–31. 10.1007/s10096-002-0758-5 - DOI - PubMed
    1. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. (1996) 71:5–13. 10.4065/71.1.5 - DOI - PubMed
    1. Zahar JR, Robin M, Azoulay E, Fieux F, Nitenberg G, Schlemmer B. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis. (2002) 35:929–34. 10.1086/342338 - DOI - PubMed
    1. Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis. (2014) 20:1490–7. - PMC - PubMed

Associated data